微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > Proton Pump Inhibitor
Proton Pump Inhibitor

消化

关键词消化 药物 抑制胃酸分泌

词汇介绍

拓展阅读

解析

proton 英 [ˈprəʊtɒn] 美 [ˈproʊtɑ:n]

释义   n. [物] 质子

例句   There is more than one proton in the nucleus..有超过一个以上的质子在核子里。

 

pump 英 [pʌmp] 美 [pʌmp]

释义   n. 泵;泵送;无带浅帮女鞋;平底轻便鞋

v. 抽吸;喷出;注入;射向目标;打气;(非正式)盘问;剧烈上下晃动;让……使用大量药物;洗胃;增加数值

例句   This is called the lymphatic pump. 这叫作淋巴泵。

 

inhibitor 英 [ɪnˈhɪbɪtə(r)] 美 [ɪnˈhɪbɪtɚ]

释义   n. [助剂] 抑制剂,抗化剂;抑制者

例句   An ErbB2 tyrosine kinase inhibitor down-regulates survivin, inducing apoptosis. 一种ErbB2酪氨酸激酶抑制剂下调生存素表达,诱导细胞凋亡。


概述

质子泵抑制药(proton pump inhibitor ,PPI)是继H2受体阻断药后的一类重要的抑制胃酸分泌药,也是目前抑制胃酸分泌作用最强的一类药物。目前临床常见的本类药物有奥美拉唑,兰索拉唑,泮托拉唑,雷贝拉唑和艾司奥美拉唑等。 作用机制质子泵(H+-K+-ATP酶)抑制剂抑酸作用并不在于阻断各种受体,而是进入胃壁细胞分泌小管的高酸环境中与H +结合形成有活性的次黄酸和次黄酰胺,与H+ -K+ -ATP酶的巯基脱水偶联,导致体内H+-K+-ATP酶活性永

Chronic Use of Proton-Pump Inhibitors and Iron Status in Renal Transplant Recipients复制标题

肾移植受者质子泵抑制剂的慢性使用和铁状态

发表时间:2019-09-03

影响因子:5.7

作者: Rianne M. Douwes

期刊:Journal of Clinical Medicine

Proton-pump inhibitor (PPI) use may influence intestinal iron absorption. Low iron status and iron deficiency (ID) are frequent medical problems in renal transplant recipients (RTR). We hypothesized that chronic PPI use is associated with lower iron status and ID in RTR. Serum iron, ferritin, transferrin saturation (TSAT), and hemoglobin were measured in 646 stable outpatient RTR with a functioning allograft for≥1 year from the "TransplantLines Food and Nutrition Biobank and Cohort Study" (NCT02811835). Median time since transplantation was 5.3 (1.8-12.0) years, mean age was 53 ± 13 years, and 56.2% used PPI. In multivariable linear regression analyses, PPI use was inversely associated with serum iron (β = -1.61, p = 0.001), natural log transformed serum ferritin (β = -0.31, p < 0.001), TSAT (β = -2.85, p = 0.001), and hemoglobin levels (β = -0.35, p = 0.007), independent of potential confounders. Moreover, PPI use was independently associated with increased risk of ID (Odds Ratio (OR): 1.57; 95% Confidence Interval (CI )1.07-2.31, p = 0.02). Additionally, the odds ratio in RTR taking a high PPI dose as compared to RTR taking no PPIs (OR 2.30; 95% CI 1.46-3.62, p < 0.001) was higher than in RTR taking a low PPI dose (OR:1.78; 95% CI 1.21-2.62, p = 0.004). We demonstrated that PPI use is associated with lower iron status and ID, suggesting impaired intestinal absorption of iron. Moreover, we found a stronger association with ID in RTR taking high PPI dosages. Use of PPIs should, therefore, be considered as a modifiable cause of ID in RTR.

译文

质子泵抑制剂(PPI)的使用可能会影响肠道铁的吸收。低铁状态和缺铁(ID)是肾移植受者(RTR)中经常出现的医学问题。我们假设慢性PPI的使用与RTR中较低的铁状态和ID相关。血清铁,铁蛋白,转铁蛋白饱和度(TSAT)和血红蛋白在来自“TransplantLines Food and Nutrition Biobank and Cohort Study”(NCT02811835)的646个稳定门诊RTR中测量,其具有≥1年的功能同种异体移植物。移植后的中位数时间为5.3(1.8-12.0)年,平均年龄为53±13岁,56.2%使用PPI。在多变量线性回归分析中,PPI使用与血清铁呈负相关(β= -1.61,p = 0.001),自然对数转换血清铁蛋白(β= -0.31,p <0.001),TSAT(β= -2.85,p = 0.001)和血红蛋白水平(β= -0.35,p = 0.007),与潜在的混杂因素无关。此外,PPI使用与ID风险增加独立相关(优势比(OR):1.57; 95%置信区间(CI)1.07-2.31,p = 0.02)。此外,与不服用PPI的RTR(OR 2.30; 95%CI 1.46-3.62,p <0.001)相比,RTR服用高PPI剂量的优势比高于服用低PPI剂量的RTR(OR:1.78; 95) %CI 1.21-2.62,p = 0.004)。我们证明PPI的使用与较低的铁状态和ID相关,表明肠道对铁的吸收受损。此外,我们发现在服用高PPI剂量的RTR中与ID的关联性更强。因此,PPI的使用应被视为RTR中ID的可修改原因。